Vyant Bio to Present at the H.C. Wainwright Global Investment Hybrid Conference
Cherry Hill, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will be participating in the H.C. Wainwright Global Investment Hybrid Conference. The event is being held from May 23-26, 2022. Registered attendees can access the recorded presentation on-demand (24x7) for the duration of the conference.
|Conference Date:||May 23-26, 2022 (Monday-Thursday)|
|On-Demand Starts:||7:00 am ET - Monday, May 23, 2022|
|On-Demand Ends:||7:00 pm ET- Thursday, May 26, 2022|
During the presentation, Vyant Bio’s Chief Executive Officer, Jay Roberts will be discussing key milestones and achievements on the scientific, business, and strategic fronts. The presentation slides will also be available in the Investors’ section of the Vyant Bio website.
If you are an institutional investor and would like to participate in this event, please click on the following link (https://hcwevents.com/globalconference/) to register for the H.C. Wainwright Global Investment Hybrid Conference. Once your registration is confirmed, you will be prompted to log into the conference website and will be able to request a one-on-one meeting with the Company.
Vyant Bio will also be available for virtual outside 1:1 meetings after the H.C. Wainwright Global Investment Hybrid Conference. Please contact Jennifer K. Zimmons, PhD at firstname.lastname@example.org or +1 917.214.3514 for scheduling.
ABOUT VYANT BIO, INC.
Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics. Vyant Bio has built a platform of therapeutics seeking to treat neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett Syndrome (“Rett”), CDKL5 Deficiency Disorders (“CDD”), and Parkinson’s Disease. The Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to de-risk candidate selection, with the goal of improving the potential effectiveness of drugs discovered earlier in the development cycle. Vyant Bio’s management believes that drug discovery needs to progressively shift to more efficient methods as the widely used models for predicting safe and effective drugs have under-performed, as evidenced by the significant time and cost of bringing novel drugs to market. By combining sophisticated data science capabilities with highly functional human cell derived disease models, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates, and create a unique approach to assimilating data that supports decision making iteratively throughout the discovery phase of drug development to identify both novel and repurposed CNS therapeutic candidates.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, the efficacy of our drug screening and discovery process, and potential for our services, future revenues or growth in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability, adapt to the global coronavirus pandemic, raise capital to meet our liquidity needs, and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2021, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.
Jennifer K. Zimmons, PhD, MBA
Zimmons International Communications, Inc.
Source: Vyant Bio, Inc.
Released May 19, 2022